Yakult Central Institute, Kunitachi-shi, Tokyo, Japan.
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Sci Rep. 2024 Aug 20;14(1):19387. doi: 10.1038/s41598-024-69923-1.
Dogs diagnosed with chronic enteropathy (CE) or small-cell lymphoma (SCL) exhibit marked differences in faecal microbiota and organic acid profiles compared with healthy dogs, as well as immune abnormalities in intestinal mucosal tissue. However, few studies have analysed trace organic acids, such as succinic acid, which have been suggested to be associated with IBD in humans. Therefore, in this study, we compared the faecal microbiota and organic acid profiles as well as serum inflammatory markers between dogs with disease (n = 11; 6 with CE and 5 with SCL) and healthy controls (n = 16). We also performed machine learning and correlation analysis to obtain more detailed insights into the characteristics of affected dogs. These results revealed that dogs with CE and SCL had lower levels of Erysipelotrichaceae (e.g. Turicibacter and Allobaculum), exhibited abnormalities in the succinic acid metabolism (i.e. succinic acid accumulation and decreased levels of Phascolarctobacterium as succinic acid-utilising bacteria) and increased levels of pathobiont bacteria such as Escherichia-Shigella. Additionally, the presence of Dubosiella was significantly negatively correlated with Canine Inflammatory Bowel Disease Activity Index scores. These findings are expected to aid the development of microbiome-based medications and/or supplements, although further verification is needed.
患有慢性肠炎(CE)或小细胞淋巴瘤(SCL)的犬与健康犬相比,粪便微生物群和有机酸谱存在明显差异,同时肠道黏膜组织也存在免疫异常。然而,很少有研究分析痕量有机酸,如琥珀酸,其被认为与人类的 IBD 有关。因此,在这项研究中,我们比较了疾病犬(n=11;6 只为 CE,5 只为 SCL)和健康对照组(n=16)的粪便微生物群和有机酸谱以及血清炎症标志物。我们还进行了机器学习和相关性分析,以更详细地了解受影响犬的特征。这些结果表明,CE 和 SCL 犬的 Erysipelotrichaceae 水平较低(例如 Turicibacter 和 Allobaculum),琥珀酸代谢异常(即琥珀酸积累和作为琥珀酸利用菌的 Phascolarctobacterium 水平降低),以及条件致病菌如 Escherichia-Shigella 水平升高。此外,Dubosiella 的存在与犬炎症性肠病活动指数评分呈显著负相关。这些发现有望有助于开发基于微生物组的药物和/或补充剂,但需要进一步验证。